logo
Robot surgery on humans could be trialled within decade after success on pig organs

Robot surgery on humans could be trialled within decade after success on pig organs

The Guardian10-07-2025
Automated surgery could be trialled on humans within a decade, say researchers, after an AI-trained robot armed with tools to cut, clip and grab soft tissue successfully removed pig gall bladders without human help.
The robot surgeons were schooled on video footage of human medics conducting operations using organs taken from dead pigs. In an apparent research breakthrough, eight operations were conducted on pig organs with a 100% success rate by a team led by experts at Johns Hopkins University in Baltimore in the US.
The Royal College of Surgeons in the UK called it 'an exciting development that shows great promise', while John McGrath, a leading expert on robotic surgery in the UK, called the results 'impressive' and 'novel' and said it 'takes us further into the world of autonomy'.
It opens up the possibility of replicating, en masse, the skills of the best surgeons in the world.
The technology allowing robots to handle complex soft tissues such as gallbladders, which release bile to aid digestion, is rooted in the same type of computerised neural networks that underpin widely used artificial intelligence tools such as Chat GPT or Google Gemini.
The surgical robots were slightly slower than human doctors but they were less jerky and plotted shorter trajectories between tasks. The robots were also able to repeatedly correct mistakes as they went along, asked for different tools and adapted to anatomical variation, according to a peer-reviewed paper published in the journal Science Robotics.
The authors from Johns Hopkins, Stanford and Columbia universities called it 'a milestone toward clinical deployment of autonomous surgical systems'.
Almost all the 70,000 robotic procedures carried out annually in the NHS in England were fully controlled under human instruction, with only bone-cutting for hip and knee operations semi-autonomous, McGrath said. Last month the health secretary, Wes Streeting, said increasing robotic surgery was at the heart of a 10-year plan to reform the NHS and cut waiting lists. Within a decade, the NHS has said, nine in 10 of all keyhole surgeries will be carried out with robot assistance, up from one in five today.
In the Johns Hopkins trial, the robots took just over five minutes to carry out the operation, which required 17 steps including cutting the gallbladder away from its connection to the liver, applying six clips in a specific order and removing the organ. The robots on average corrected course without any human help six times in each operation.
'We were able to perform a surgical procedure with a really high level of autonomy,' said Axel Krieger, assistant professor of mechanical engineering at Johns Hopkins. 'In prior work, we were able to do some surgical tasks like suturing. What we've done here is really a full procedure. We have done this on eight gallbladders, where the robot was able to perform precisely the clipping and cutting step of gallbladder removal without any human intervention.
'So I think it's a really big landmark study that such a difficult soft tissue surgery is possible to do autonomously.'
McGrath, who chairs NHS England's robotics steering committee, said autonomous surgery, while still years away, could one day lead to a human surgeon overseeing several autonomous robotic operations at the same time, carrying out simple procedures such as hernia operations or gall bladder removals more rapidly, with greater precision than humans and with less damage to surrounding bodily structures.
But he cautioned that autonomous surgery remained a long way from being clinically deployable, because tests on dead pig organs do not test the robots' capacity to react to a patient moving and breathing, blood running in the field of operation, an inadvertent injury, smoke from cauterisation or fluid on the camera lens.
Nuha Yassin, who leads on robotic surgery at the Royal College of Surgeons of England, said: 'The next step must involve a careful exploration of the nuances within this rapidly evolving field to assess how these findings can be safely and effectively translated into a human pilot. Only then can this approach move toward, becoming a sustainable model for the future.'
She said training, education and patient safety must remain at the forefront.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US appeals court extends suspension of 98-year-old judge in fitness probe
US appeals court extends suspension of 98-year-old judge in fitness probe

Reuters

time8 minutes ago

  • Reuters

US appeals court extends suspension of 98-year-old judge in fitness probe

WASHINGTON, July 28 (Reuters) - The U.S. Court of Appeals for the Federal Circuit said on Monday that it would extend its suspension of 98-year-old judge Pauline Newman for another year after determining that she had not complied with an internal investigation into her fitness to serve on the Washington, D.C.-based court. A committee of the court's active judges determined, opens new tab that reports from doctors chosen by Newman did not eliminate the need for her to undertake "a full neuropsychological battery of tests" to ascertain whether she was capable of continuing to serve. Newman's attorney Greg Dolin said on Monday that the committee did not take sufficient time to consider their arguments, noting that the court published its 90-page opinion just days after a July 24 hearing on the suspension. "The idea that they took anything we said seriously" was "just laughable," he told Reuters. Dolin argued during the hearing that the court had enough information from several medical experts to resolve the investigation and end Newman's suspension, according to a transcript. A spokesperson for the Federal Circuit declined to comment on the ruling. Newman is the oldest federal judge not to have taken a form of semi-retirement known as senior status. Appointed to the Federal Circuit by Republican President Ronald Reagan in 1984, Newman is a respected patent jurist and a prominent dissenter at the Washington, D.C.-based court, which frequently rules on high-stakes intellectual property cases involving major companies. The Federal Circuit's chief judge, Kimberly Moore, said in orders made public in 2023 that Newman had shown signs of serious cognitive and physical impairment. The court suspended Newman later that year after finding that she had refused to cooperate with an investigation into her fitness. Newman has maintained that she is fit to serve and sued the council over her suspension. A judge dismissed her case last year, and a separate federal appeals court in Washington is currently considering whether to revive it. Newman has submitted reports from neurologists vouching for her mental fitness. The court on Monday expressed concerns about the reports' credibility, finding that they contained misstatements about her health and that her medical records contained concerns about fainting episodes and impaired memory. "The expanded record leaves no doubt that the neuropsychological testing ordered by the committee from the outset is necessary," the court said.

Bristol Myers, Bain Capital form new company to develop immunology drugs
Bristol Myers, Bain Capital form new company to develop immunology drugs

Reuters

time8 minutes ago

  • Reuters

Bristol Myers, Bain Capital form new company to develop immunology drugs

July 28 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain's $300 million financing round, the companies said on Monday. The new company will work on five experimental drugs licensed from Bristol Myers, including a late-stage lupus treatment and a mid-stage psoriasis drug that has shown promise in trials. Bristol Myers will retain nearly 20% equity in the venture and is set to receive royalties and milestone payments based on the drugs' success. The collaboration allows the drugmaker to concentrate its immunology research on treatments aimed at resetting the immune system while ensuring the continued development of promising assets, the companies said. "These assets have significant potential, and we are confident that this new company will drive their development to ensure greater impact for patients," said Julie Rozenblyum, senior vice president of business development at Bristol Myers. Daniel Lynch, a seasoned pharmaceutical executive, will take on the roles of executive chairman and interim CEO of the new company, while Bristol Myers' chief research officer Robert Plenge is set to join the board alongside Bain Capital partners. Canada Pension Plan Investment Board also participated in the financing round.

Universal Health Services beats quarterly profit estimates on higher medical care demand
Universal Health Services beats quarterly profit estimates on higher medical care demand

Reuters

time8 minutes ago

  • Reuters

Universal Health Services beats quarterly profit estimates on higher medical care demand

July 28 (Reuters) - U.S. hospital operator Universal Health Services (UHS.N), opens new tab beat Wall Street estimates for second-quarter profit on Monday, driven by sustained demand for medical care services. Health insurers have flagged elevated demand and costs in individual Affordable Care Act (Obamacare) and Medicaid plans for low-income individuals, which could benefit hospital operators. Last week, larger peer HCA Healthcare (HCA.N), opens new tab beat quarterly profit estimates but saw its shares decline amid concerns over impending changes to Medicaid and Obamacare insurance plans under the Trump administration. Universal Health's same-facility adjusted admissions increased by 2% at acute care hospitals during the quarter, while admissions at behavioral healthcare facilities grew by 0.4%. The company now sees its 2025 revenue to be between $17.10 billion and $17.31 billion, compared to the previously expected range of $17.02 billion to $17.36 billion. Analysts, on average, expect 2025 revenue of $17.14 billion, according to data compiled by LSEG data. For the quarter ended June 30, the King Of Prussia, Pennsylvania-based company reported an adjusted profit of $5.43 per share, beating estimates of $4.92 per share. Investors are currently focused on how hospital operators will address potential tariffs affecting global supply chains for medical devices and surgical equipments. The sector is also preparing for the expiry of Obamacare subsidies next year, a change expected to impact patient coverage, raise insurance premiums and reduce enrollment numbers, potentially leaving hospitals responsible for increased uncompensated care costs.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store